The Phase 3 study (NCT04930094) investigating secukinumab for patients with Giant Cell Arteritis (GCA) completed its primary data collection on 2025-04-11. This trial enrolled 354 participants to evaluate the efficacy and safety of secukinumab in combination with a glucocorticoid taper regimen.
Background
The Phase 3 study (NCT04930094) aimed to evaluate the efficacy and safety of secukinumab in patients with Giant Cell Arteritis (GCA). The trial investigated secukinumab in combination with a glucocorticoid taper regimen, comparing it against a placebo arm also combined with a glucocorticoid taper regimen.
Trial design
The NCT04930094 study was a Phase 3, randomized, placebo-controlled trial that enrolled 354 participants. The study investigated secukinumab in patients diagnosed with Giant Cell Arteritis (GCA). Participants received either secukinumab 300 mg or secukinumab 150 mg, or a placebo, all in combination with a glucocorticoid taper regimen. The trial's overall status is listed as COMPLETED.
What this means
The completion of primary data collection for this Phase 3 study marks a significant step in the evaluation of secukinumab for Giant Cell Arteritis (GCA). The trial's findings, once analyzed and released, will provide crucial insights into the efficacy and safety profile of secukinumab when used with a glucocorticoid taper regimen for this condition.
Source
The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The study record for NCT04930094, titled "Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)," was updated on 2025-04-11 on clinicaltrials.gov.